跳至主要内容
临床试验/NCT00675051
NCT00675051已完成不适用

Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension

University of California, San Francisco1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2008年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1

研究概览

简要总结

Pulmonary hypertension is a progressive and life threatening condition. It is characterized by severe remodeling of the pulmonary vessel wall, obstructive plexiform lesions, multi-focal thrombosis, and enhanced vasoconstriction. All of these characteristics contribute to increased pulmonary vascular resistance.

Circulating endothelial microparticles (EMPs) play an integral role in the pathogenesis and perpetuation of pulmonary hypertension. Levels of EMPs are considered a reliable biological parameter of endothelial injury.

We propose to assess the evolution of both circulating and pulmonary venous EMPs in patients with PH. Assessments will be made before and after initiation of Endothelin-1 (ET-1) Receptor blocker therapy, and correlated to their patterns with the changes in mean PAP, the 6 Minutes Walking Distance test, and circulating Endothelin-1 values. Measurements of the endothelial microparticle circulating levels (assessed by flow cytometry methods) will be made before, 1 month and 3 months after initiation of therapy.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient's + 18 years with suspected pre-capillary pulmonary hypertension
  • Prescribed Endothelial - 1 receptor blocker

排除标准

  • Currently taking endothelium-active vasodilator therapy.
  • Hemoglobin and / or hematocrit level blood the lower normal limit.
  • Left ventricle dysfunction (LVEF <50%)
  • LV end-diastolic pressure > 15 mmHg)
  • Recent history (<3 months) of pulmonary embolism
  • Liver failure or abnormal liver function tests; aortic or mitral regurgitation or stenosis
  • Current medication with endothelin-1 receptor antagonist, prostacyclin analogues or type 5 phosphodiesterase inhibitors.
  • Subjects with conditions known to be associated with an increase in circulating endothelial microparticle numers, such as chronic renal failure (Creatinine Clearance < 50 ml/min/m2) acute coronary syndromes and uncontrolled system hypertension.

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yerem Yeghiazarians

Professor of Clinical Medicine

University of California, San Francisco

研究点 (1)

Loading locations...

相似试验